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Abstract
Background: The immunological mechanisms responsible for protection against malaria infection vary among 
Plasmodium species, host species and the developmental stage of parasite, and are poorly understood. A challenge 
with live parasites is the most relevant approach to testing the efficacy of experimental malaria vaccines. Nevertheless, 
in the mouse models of Plasmodium berghei and Plasmodium yoelii, parasites are usually delivered by intravenous 
injection. This route is highly artificial and particularly in the P. berghei model produces inconsistent challenge results. 
The initial objective of this study was to compare an optimized intravenous (IV) delivery challenge model with an 
optimized single infectious mosquito bite challenge model. Finding shortcomings of both approaches, an alternative 
approach was explored, i.e., the subcutaneous challenge.
Methods: Mice were infected with P. berghei sporozoites by intravenous (tail vein) injection, single mosquito bite, or 
subcutaneous injection of isolated parasites into the subcutaneous pouch at the base of the hind leg. Infection was 
determined in blood smears 7 and 14 days later. To determine the usefulness of challenge models for vaccine testing, 
mice were immunized with circumsporozoite-based DNA vaccines by gene gun.
Results: Despite modifications that allowed infection with a much smaller than reported number of parasites, the IV 
challenge remained insufficiently reliable and reproducible. Variations in the virulence of the inoculum, if not properly 
monitored by the rigorous inclusion of sporozoite titration curves in each experiment, can lead to unacceptable 
variations in reported vaccine efficacies. In contrast, mice with different genetic backgrounds were consistently 
infected by a single mosquito bite, without overwhelming vaccine-induced protective immune responses. Because of 
the logistical challenges associated with the mosquito bite model, the subcutaneous challenge route was optimized. 
This approach, too, yields reliable challenge results, albeit requiring a relatively large inoculum.
Conclusions: Although a single bite by P. berghei infected Anopheles mosquitoes was superior to the IV challenge route, 
it is laborious. However, any conclusive evaluation of a pre-erythrocytic malaria vaccine candidate should require 
challenge through the natural anatomic target site of the parasite, the skin. The subcutaneous injection of isolated 
parasites represents an attractive compromise. Similar to the mosquito bite model, it allows vaccine-induced 
antibodies to exert their effect and is, therefore not as prone to the artifacts of the IV challenge.
Background
Despite decades of research, malaria infection remains a
major global health problem with high mortality and
morbidity. Efforts to disrupt the life cycle of the parasite
by controlling the vector have had only limited success,
while the usefulness of anti-malarial drugs is hampered
by their lack of availability to those most in need and to
the rapid evolution of drug resistant parasites. An effec-
tive vaccine remains the most promising approach to
controlling the disease [1], but is still not available.
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Research on malaria vaccines is complicated by the lack
of surrogate markers of protection and the complexity of
the parasite life cycle. To complicate matters, reported
mechanisms of protection against the liver stage of the
parasite differ not only between human and rodent
malaria species, but also between different rodent
malaria species. Therefore, infection of vaccinated ani-
mals with live parasites, as has previously been used to
evaluate anti-malarial drugs, remains the most, if not
only, meaningful readout of vaccine efficacy [2,3]. Such a
challenge model should meet the following requirements:
1) reproducible infection of a predictable proportion of
the challenge cohort; 2) establishment of infection using
numbers of parasites consistent with natural infection,
and 3) a predictable time to patency. The most frequently
used method for challenging animals with malaria is the
intravenous (tail vein) injection of parasites isolated from
the salivary glands of Anopheles  mosquitoes. This
method was first described for the Plasmodium berghei
model almost four decades ago [4] and has not signifi-
cantly evolved since. In this method, mice are injected
with a defined number of sporozoites. However, the num-
ber of sporozoites required to infect 90-100% of the mice
ranges from 30 to 5,000 sporozoites. This number also
v a r i e s  w i d e l y  f r o m  d a y  t o  d a y ,  f r o m  m o u s e  s t r a i n  t o
mouse strain and from lab to lab (personal observation
and [4-7]). The significant variability may be a conse-
quence of changes in sporozoite virulence or to host
response to extraneous materials in the inoculum such as
mosquito debris, salivary gland flora, or dead sporozoites
[8]. In addition, differences reported by different labora-
tories are presumably exacerbated by the use of labora-
tory-specific isolates and sub-strains of the parasite.
Obtaining consistent IV infection of the frequently used
BALB/c mice has been especially problematic. Scheller
and colleagues approached establishing an effective chal-
lenge model by using gradient centrifugation to purify
parasites [6]. Purification of sporozoites by this method
produced more reproducible infections, but also required
5,000 sporozoites per inoculum, which is far larger an
amount than the 25 to 250 sporozoites estimated to be
inoculated during a mosquito bite challenge [9-11].
In addition to the technical problems associated with
the IV challenge model, the approach also raises very
serious scientific concerns. In contrast to the IV injected
parasites, Plasmodium delivered by their arthropod vec-
tor, the Anopheles mosquito, are not injected directly into
the blood stream, but rather into avascular portions of
the skin from where they travel into the liver over an
extended period of time [11,12]. It is unclear how this
transient existence of the parasite in host tissue outside
the hepatocytes affects its viability. Recent evidence sug-
gests that a good proportion of injected sporozoites
either remain close to the entry site in the dermis or reach
the lymph node [11]. It remains to be determined what
the consequence of these different pathways is for mount-
ing of a host immune response. Convincing evidence
already exists that bypassing this extra-hepatic phase can
lead to unacceptable conclusions regarding effector
mechanism when analyzing vaccine-induced protection
against liver stage infection. For instance, in one study,
sporozoites delivered to the skin by a mosquito were rap-
idly immobilized by sporozoite-antigen specific antibod-
ies while still in the skin [13]. In another study where the
IV challenge was used to determine the effector mecha-
nism of a genetically-attenuated sporozoite vaccine,
CD8+ T-cells were implicated in immune protection [14].
T h i s  c o n c l u s i o n  i s  l i k e l y  i n c o m p l e t e  s i n c e  v a c c i n e -
induced antibodies did not have the opportunity to exert
their effect as the transit time of the IV injected parasites
from injection site to the liver was too short [15]. The
impact of the challenge route on the efficacy of a passive
(monoclonal anti-CSP antibodies) P. berghei vaccine was
also observed in a side-by-side comparison of the IV and
mosquito bite challenge in the P. berghei model of CD-1
mice [16]. The outcome of this study, however, was
reversed with antibody-injected mice appearing better
protected after IV challenge than mosquito bite infection.
In the Plasmodium yoelii model, others were unable to
obtain reliable challenge results in BALB/c mice by using
varying numbers of infected Anopheles stephensi mosqui-
toes [17], which is unexpected in light of the sensitivity of
this mouse strain to P. yoelii [7]. Despite the obvious
shortcomings, the IV challenge model nevertheless con-
tinues to be used for reporting malaria vaccine efficacy
[18-20].
An alternative challenge approach introduced several
decades ago is through the bite of an infectious mosquito,
the natural delivery route of transmission [21]. This is
also the method of choice for the challenge of human vol-
unteers in P. falciparum vaccine trials [22-25]. To date, no
candidate vaccine has shown reproducible field efficacy
without demonstration of efficacy in a clinical challenge
trial using this approach [26]. However, the mosquito bite
challenge is rarely employed in mouse models of malaria.
The primary reasons for this are that it is more labour
intensive requiring more and better trained personnel,
and well established conditions for a mosquito bite chal-
lenge of mice are not readily available. While the number
of sporozoites delivered by a single bite of an infected
mosquito may still not precisely be known [9,10], another
study using PCR to detect parasite RNA in the liver forty
hours after a blood meal concluded that the inoculum
from a single mosquito bite is quite consistent [27]. These
observations indicated the need for optimizing the mos-
quito bite challenge model to consistently deliver the
same inoculum. This can be accomplished by only chal-
lenging with a single infected mosquito. ProtectiveLeitner et al. Malaria Journal 2010, 9:145
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immunity may be overwhelmed when using the previ-
ously described bulk-challenge method [28] in which a
pool of mosquitoes with an unknown and variable
infected portion are allowed to feed.
The objective of this study was to first optimize and
then compare the IV with the single mosquito bite chal-
lenge method and characterize the parameters required
to reliably challenge mice. The mosquito bite challenge
method described here was successfully used to deter-
mine the efficacy of the first P. berghei CSP DNA vaccine
[29,30]. The single mosquito bite challenge is clearly
superior to the IV injection of isolated parasites thus con-
firming the conclusions of others who only used the CD-
1 mouse model [16]. However, the increased need for
manpower and longer duration of a mosquito bite chal-
lenge, especially for large-scale vaccine studies represent
a significant hurdle for its acceptance. Therefore, atten-
tion was focused on a compromise approach, the subcu-
taneous injection of isolated parasites into the inguinal
site of mice [31-33]. This approach combines the target-
ing of the correct anatomical site for the delivery of para-
sites with the ease of the intravenous injection, while
eliminating the need to prepare the mice for the proce-
dure (i.e., warming them for IV injection or anesthetizing
them for mosquito-bite challenge) and produces highly
reproducible challenge outcomes.
Methods
Mice and parasites
Female, 4-6 wk-old, BALB/c, C57BL/6, and ICR (CD-1)
mice were obtained from The Jackson Labs. CD-1 mice
for the subcutaneous challenge experiments were from
Harlan Sprague-Dawley. ANKA strain P. berghei parasites
were maintained at the Division of Entomology
(WRAIR). For needle-based challenges, parasites were
isolated from mosquito salivary glands 26 to 28 days after
infection without further purification.
IV challenge
Parasites were delivered by using a 1.0 ml tuberculin
syringe and a 30 gauge needle. Sporozoites were dissected
into M199 medium (GIBCO/Invitrogen) containing 5%
normal BALB/c mouse serum (Harlan Bioproducts for
Science Inc., Indianapolis, IN) which was standardized
and pathogen screened. All further manipulations and
dilutions of sporozoites were with this medium. Diluted
sporozoites were maintained on ice until use within two
hours. For challenge, mice were warmed via a heat lamp
and injected IV with 100 μl of a sporozoite suspension
containing from 10-10,000 sporozoites.
Mosquito bite challenge
Anopheles stephensi mosquitoes were placed into small,
sealed, screened containers. Mice were sedated with a 0.1
ml intraperitoneal injection of a mixture containing 25
mg/ml Ketaset® (ketamine HCL, Wyeth/Pfizer, New York,
NY) and 5 mg/ml Rompun® (xylazine HCL, Bayer, Pitts-
burgh, PA) in sterile saline. Sedated animals were placed
individually on the containers until it was observed that a
blood meal had been taken. The sex and number of the
m o s q u i t o e s  i n  e a c h  c a r t o n  w e r e  m o n i t o r e d  a n d  c o n -
trolled during all experimental procedures. An infectious
mosquito bite was confirmed by dissection of the mos-
quito salivary glands and viewed by phase-contrast
microscopy. If no sporozoites were observed, this process
was repeated until an infected mosquito was identified.
Subcutaneous inguinal challenge
Parasites were isolated and injected as described above
for IV challenge, but delivered to the subcutaneous pouch
at the base of the hind leg of mice. This route was chosen
because it is easily accessible and holds larger amounts of
liquid than other subcutaneous sites.
Monitoring infection
Blood stage infection was determined in challenged ani-
mals by Giemsa-stained thin blood films. Thin blood
films were prepared on days 7 and 14 by removing a less
than 1 mm section of the distal end of the tail and spot-
ting approximately 3 μl of blood onto a microscope slide.
Slides were air dried, fixed with 100% methanol and
stained with a 10% Giemsa solution for 10 minutes at
room temperature. Slides were evaluated at a 1000× mag-
nification (oil-immersion) using a Nikon E400 Eclipse
microscope by reading 20 fields per slide.
Vaccination of mice with a DNA vaccine
In order to evaluate the challenge models under vaccine
trial conditions, mice were vaccinated with DNA vaccines
encoding the P. berghei CSP gene previously reported to
protect mice against challenge [29,31]. Briefly, a plasmid
containing the full length CSP-gene of P. berghei [29]
(designated here CSP(+)) was used for the initial experi-
ments. For subsequent independent experiments, a plas-
mid encoding the full length CSP without the GPI anchor
sequence (designated CSP(-A)) was employed. The CSP(-
A) plasmid yields increased vaccine efficacy compared to
the full length CSP(+) construct [34]. Plasmids were
grown in E. coli and purified by double banding on
cesium chloride gradients followed by chromatography
on Qiagen columns (Valencia, CA) according to manu-
facturer's recommendation. DNA was precipitated on
gold beads and used to vaccinate mice epidermally by
gene gun delivery targeting two sites of the shaved
abdominal area with 1 μg DNA dose each. When using
the CSP(+) plasmids, animals were immunized two times
at four-week-intervals and challenged two weeks after the
last immunization. When using the CSP(-A) plasmid,Leitner et al. Malaria Journal 2010, 9:145
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mice received three immunizations at four-week inter-
vals.
Statistical analysis
In order to achieve an 84% chance to detect a statistical
difference between an infection rate of 80% (a negative
control rate) and an infection rate of 10% (a non-control
infection rate), using Fisher's exact test (2-sided, with
alpha = 0.05), ten mice per group were required (nQuery
Advisor 6.0 software, Statistical Solutions, Saugus, MA).
Results
Challenge efficiency for IV and mosquito bite challenge
The number of IV injected sporozoites required to reli-
ably challenge all or most (i.e., at least 90%) naïve controls
(referred to as "challenge controls" thereafter to distin-
guish from vaccination controls) varies widely in the liter-
ature. For all IV challenge studies performed, a range of
sporozoite doses was used (100 - 10,000) that included
those reported by others. These data reveal that a stan-
dard IV challenge dose of 300 sporozoites infected 90% or
more of naive BALB/c mice in 11 of 18 experiments (63%
of the time). For these challenges, the mean ID50 (defined
as the calculated number of sporozoites required to infect
50% of naive mice) was 50 ± 15 sporozoites (Table 1). In
the remaining experiments with BALB/c mice, less than
90% of the challenge controls were infected, with a mean
ID50 of 259 ± 78 sporozoites. The mean ID50's for infect-
ing naïve C57BL/6 and ICR (CD-1) mice was 19 and 18
sporozoites, respectively.
By using the single mosquito bite challenge in BALB/c
mice, a mean of 98% of challenge controls were infected
in at least 80% of the challenge experiments performed.
In replicate experiments with C57BL/6 and ICR (CD-1)
mice, 100% of naïve animals were infected 100% of the
time (Table 1).
Conditions for an effective single bite challenge
In initial experiments, variations in feeding times by the
single female mosquito in the container were observed.
Interestingly , these variations seemed to be affected by
the presence of male mosquitoes, which were often unin-
tentionally co-transferred to the feeding container. To
address this observation, the time between mosquito
transfer to the container and initiation of feeding (prob-
ing) as well as the overall feeding time of a single malaria-
infected or non-infected female mosquitoes were deter-
mined in the presence of varying numbers of male or
female mosquitoes (Table 2). Age and batch-matched
infected female mosquitoes required at least 45% more
time to consummate a blood meal than did non-infected
females. Adding two male mosquitoes to the challenge
carton reduced the mean feeding time for an infected
female to rates that were equivalent to those of single
non-infected females, but had no effect on feeding time
of an uninfected female. Although the addition of two
males failed to increase the rate of probing by the infected
female during feeding, it did reduce the time until feeding
was completed. In contrast, the addition of uninfected
females to the challenge cartons did not affect the time
that an infected female required to feed.
Categorization of IV challenge failures
As expected, the mean titration curve associated with
BALB/c mouse challenges in which the ID50 was 50
sporozoites (successful challenge) was different from
experiments where the ID50 was 259 (failed chal-
lenge)(Table 1 and Figure 1). Although the curves indi-
cate that a discrete variable may be associated with
sporozoite virulence, it could not be identified in this
study. Variables that were tested include mouse age, the
nature of the protein support used during dissection and
dilution (foetal bovine or normal mouse serum, heat
Table 1: Comparison of intravenous vs. single mosquito bite challenge models
IV Challenge Single Mosquito Bite e)
Average Standard Success Average Standard Success
Mouse Strains Tested LD(50) a) Error Rate b) % Infected Error Rate
BALB/c (Success) 50c) 15 63% 98 d) 1.3 80%
BALB/c (Failed) 259 c) 78 N/A 75 d) 5N / A
C57BL/6 19 c) 0 100% 100 d) 0 100%
ICR (CD-1) 18 c) 0 100% 100 d) 0 100%
a) ID50's were calculated by the Reed-Muench method [46]
b) Success was defined as 90% or better of the naïve animals (challenge controls) being infected
c) Data obtained from 18 (BALB/c) or two (C57BL/6 and ICR (CD-1)) independent IV challenge experiments
d) Data obtained from 11 (BALB/c) or two (C57BL/6 and ICR (CD-1)) independent mosquito bite challenge experiments
e) Mice were challenged by a single infected female mosquito in the presence of two male mosquitoes (as described in Table 2)Leitner et al. Malaria Journal 2010, 9:145
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inactivated foetal bovine or mouse serum, bovine serum
albumin), pre-feeding infected mosquitoes with a blood
meal prior to dissection, and the duration of time in
which the parasite suspensions were held on ice before
use. When comparing different sources of serum protein
support, fresh mouse serum was found to promote maxi-
mal sporozoite viability (obtained from littermates of
experimental animals) compared to commercially
obtained or previously frozen mouse serum.
When an IV challenge failed because less than 90% of
challenge control animals were infected, two types of
challenge failures were observed. The first type has been
discussed above, where the ID50 for the challenge was
259 sporozoites (Type 1 challenge failure). For the second
type of failure (Type 2 challenge failure), the ID50 could
not be calculated because infectivity and challenge dose
were inversely related (Figure 2) suggesting the presence
of a parasite- or mosquito-derived contaminant. Type 2
challenge failures appeared to correlate with the use of
parasite preparations that required a larger than average
n u m be r  o f  i n f e c t ed  m o s q u i t oe s  i n  o r d e r  t o  o b t a i n  t h e
necessary number of sporozoites. Such preparations are
expected to contain higher concentrations of mosquito
debris and/or non-infectious sporozoite material.
Table 2: Sex mixed feeding populations increase mean feeding times
Exp. 1 Exp. 2
Mosquito feeding population b) Average timea)
± SE
Average timea)
± SE
1 Infected c) + 2 Uninfected Females 11.5 ± 4.3 7.7 ± 1.3
1 Infected + 1 Uninfected Female 8.7 ± 2.9 ND
1 Infected Female + 2 Males 2.4 ± 0.8 5.4 ± 0.8
1 Infected Female + 1 Male 6.2 ± 2.9 ND
1 Uninfected Female 2.4 ± 4.6 5.5 ± 3.2
1 Infected Female 8.7 ± 1.8 8.8 ± 2.4
a) Average feeding time in minutes (i.e, time between start of actual blood meal and retraction of the proboscis, excluding time spent on 
probing)
b) n = 10 BALB/c mice for each group
c) Infection status of "infected" mosquitoes was confirmed after a successful blood meal
Figure 1 Titration of sporozoites for intravenous challenge. Naïve BALB/c mice (10 per group) were challenged with titered numbers of P. berghei 
SPZ by IV (tail vein) injection. Data are compiled from 18 independent challenge experiments. Challenges were arbitrarily considered to have been 
successful (solid line) when at least 90% of the mice challenged with 300 SPZ were infected (as determined by parasitemia 14 days after challenge) or 
failed (dotted line) when less than 90% of mice challenged with 300 SPZ were infected. N = 10 mice/group for each experiment. Shown are the aver-
age numbers of infected animals from independent challenge experiments ± SEM.
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Varying IV challenge strength and its impact on reported 
vaccine efficacy
The reproducibility of a challenge is a central prerequisite
for any vaccine study. The requirement to obtain high
quality sporozoites for use in a challenge can be associ-
ated with varying sporozoite viability, which then may
affect the protective efficacy induced by a vaccine. When
using the IV challenge model, even within experiments
which were defined as 'successful challenges' (where 90%
or more of challenge controls were infected), comparing
the outcomes from these different challenge experiments
was not possible (Table 3). In one experiment, mice were
vaccinated two times with a DNA vaccine by epidermal
injection and challenged with 300 sporozoites IV two
weeks after the last immunization. This vaccination regi-
men was chosen to avoid maxing out the antibody-
dependent protection induced by this vaccine [29]. The
ID50 for this challenge was 178 sporozoites and 70% of
the vaccinated mice were protected (p = 0.01), suggesting
that this vaccine and the vaccine regimen used were
effective. In an independent repeat experiment, three
identical groups of vaccinated mice were challenged with
30, 100, or 300 sporozoites on the same day. The ID50 for
this challenge was less than 30 sporozoites. The apparent
increased infectivity of sporozoites used for the second
experiment seemed to overwhelm the protective effects
demonstrated in the first experiment, and thus reported
poor vaccine efficacy. This, however, was contrary to the
overwhelming evidence from other challenge experi-
ments that established the efficacy of this particular vac-
cine.
The subcutaneous challenge as an alternative to the 
intravenous and bite challenge model
The subcutaneous injection of isolated sporozoites has
been proposed as an alternative to either of the two
methods described above since it appears to combine the
advantages of both. This method has already been used
successfully to test the efficacy of various P. berghei DNA
vaccine constructs [31-33]. When determining the mini-
mal dose required for a reliable infection of at least 90% of
naïve animals it became evident that a larger number of
isolated sporozoites was required than needed for the IV
challenge to infect BALB/c mice (Table 4). Interestingly,
the titration curves obtained with the subcutaneous chal-
lenge of BALB/c and ICR (CD-1) mice never resulted in a
plateau, but consistently produced a bell-shaped curve. A
standard dose of 5,000 sporozoites was chosen for BALB/
Figure 2 Analysis of failed IV challenge experiments. Failed (i.e., less than 90% of naïve mice challenged with 300 SPZ became infected) challenge 
experiments showed one of two titration patterns. Type 1 challenge failures (dotted line) showed a direct relationship between sporozoites dose and 
percent of mice infected. Type 2 failures (solid line) showed an inverse relationship between sporozoites dose and the percentage of mice infected. 
N = 10 mice/group for each experiment. Shown are the average numbers of infected animals from independent challenge experiments ± SEM.
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c mice. Challenge doses required to infect C57BL/6 and
ICR (CD-1) mice by the subcutaneous route were 100
and 15,000, respectively (Table 4).
The influence of challenge conditions on perceived vaccine 
efficacy
In contrast to the subcutaneous challenge, which reliably
infects mice when using a 'standard' dose of P. berghei
sporozoites, the inoculum required to infect through the
IV route can vary significantly. This raised the question
what impact the size of the parasite inoculum might have
on the perceived vaccine efficacy. For this purpose, the
experiment described in Table 3 was repeated with the
optimized CSP plasmid, pCSP(-A) (Table 5). This plas-
mid consistently protects the majority or all immunized
BALB/c mice from infection by subcutaneously delivered
sporozoites through an antibody-dependent mechanism
without the involvement of effector T cells [30,31,33,34].
This route was used as a reference and positive control.
Mice immunized with either the control plasmid
(pcDNA) or the CSP-plasmid (CSP(-A)) were challenged
by subcutaneous injection of a fixed dose or a titered
number of sporozoites by the intravenous route. The sub-
cutaneous challenge confirmed the high (100%) efficacy
of the CSP-based DNA vaccination. However, the
observed vaccine efficacy in IV challenged mice was
dependent on the challenge dose. Despite the fact that the
challenge was considered "successful" based on (a) the
Table 3: Inter-experimental variations of IV challenge and effect on perceived vaccine efficacy
Experiment 1 % Infected, p b) % Infected SPZ. Challenge
CSP(+) d) Naïve LD(50) )e Status
Chall. w/300 SPZ c) 30, p = 0.01 90 178 Success a)
Experiment 2 % Infected, p % Infected SPZ. Challenge
CSP(+) Naïve LD(50) Status
Chall. w/30 SPZ 70, p = 0.11 100 ID50 < 30 Success
Chall. w/100 SPZ 80, p = 0.24 100 ID50 < 30 Success
Chall. w/300 SPZ 80, p = 0.24 100 ID50 < 30 Success
a) Success was defined as being able to infect 90% or better of the challenge control animals.
b) p was calculated by Fisher-Yates Exact 2 × 2 test with native controls.
c) All experimental groups consisted of 10 BALB/c mice.
d) DNA plasmid that encodes a full-length P. berghei circumsporozoite protein.
e) ID50's were calculated by the Reed-Muench method [46] from naive titration controls.
Table 4: Sporozoite titration for subcutaneous challenge
C57BL/6a) BALB/c ICR (CD-1)
SPZ % infected SPZ % infected SPZ % infected
30 60% 1,000 0% 1,000 0%
100 100% 2,000 0% 3,000 0%
300 100% 3,000 60% 5,000 0%
4,000 90% 10,000 80%
5,000 90% 15,000 100%
8,000 80% 20,000 0%
10,000 0%
a) N = 5/group for C57BL/6 and ICR (CD-1), N=10/group for BALB/c. Shown is one representative titration experiment. Results were confirmed 
in independent repeat experiments.Leitner et al. Malaria Journal 2010, 9:145
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number of infected challenge controls at the 300 SPZ
dose, and (b) the ID50 which was consistent with that
previously established in BALB/c mice (Table 1), the per-
ceived vaccine efficacy was only 44% (for 300 SPZ) and as
low as 12.5% when challenging with 1,000 SPZ.
To further investigate the effect of the challenge route
on the perceived vaccine efficacy, BALB/c mice were
immunized twice by either intramuscular injection (50
μg/dose) or gene gun bombardment of the skin (3 shots/
immunization, 1 μg/shot) using an empty plasmid
(pcDNA) or the P. berghei CSP(-A) DNA vaccine [34],
which has previously been shown to induce strong anti-
body responses and protective immunity that appears to
be independent of effector T cells [33]. Mice were chal-
lenged in parallel either by the subcutaneous or IV route.
The subcutaneous route is comparable to the mosquito
bite challenge in that the inoculum is delivered to the
same tissue site (skin) where, in contrast to the IV chal-
lenge model, the sporozoites are capable of interacting
with antibodies for extended periods of time [13]. As pre-
dicted by Vanderberg et al [15] the challenge route signif-
icantly affected the level of protection. CSP-plasmid
immunized BALB/c mice were protected from 5000 sub-
cutaneously delivered sporozoites, but poorly/not pro-
tected from a significantly smaller inoculum (300 SPZ) of
intravenously injected sporozoites (Table 6).
Discussion
The immune mechanisms responsible for protecting
against  Plasmodium-infection or morbidity associated
with chronic infection are surprisingly still not under-
stood. This is in part due to insufficient efforts spent on
the characterization of immune correlates of protection
and to the fact that different mechanisms appear to be
required to protect against different species of Plasmo-
dium.
While cytotoxic T cells have been described as the
main effectors protecting mice against P. yoelii infection
after immunization with a CSP-based DNA vaccine [35],
CTL appeared to be irrelevant in mice protected from P.
berghei infection following immunization with a similar
vaccine [33]. In the latter study, Th2-type antibodies rec-
ognizing specific epitopes on the CS-protein correlated
with protection. Because of the lack of robust surrogate
markers of protection, challenging with live parasites
remains the most meaningful method to determine the
potential protective efficacy of a candidate vaccine for
both preclinical and clinical trials.
While vaccinated human volunteers are generally chal-
lenged through the bite of infected mosquitoes, the IV
challenge model remains the most commonly used
approach for infecting rodents with malaria because of
the relative convenience and the ability to quantitate the
sporozoite inoculum delivered. However, the number of
sporozoites required to reproducibly infect 90-100% var-
ies greatly. BALB/c mice, while frequently used for
malaria vaccine studies, are particularly difficult to infect
reliably. This may be due to the much higher susceptibil-
ity of this strain's innate immune system to P. berghei (but
not to P. yoelii), which has been known for several
decades [7] and had been used to question the usefulness
of this mouse strain for P. berghei studies [4]. Malaria
infection in general, and specific malaria-associated mol-
ecules, have been shown to trigger inflammatory
responses through the stimulation of innate immune
receptors [36-39]. Many such studies were, however, con-
ducted in vitro, and while it may be questionable whether
noticeable inflammatory responses are induced by these
Table 5: Effect of IV challenge dose on perceived vaccine efficacy
pcDNAa) pCSP(-A) a)
Challenge Infected/total Infected/total Efficacy
10,000 SPZ/IV 10/10 8/10 20%
3000 SPZ/IV 9/9 7/10 22%
1000 SPZ/IV 8/10 7/10 12.5%
300 SPZ/IV 9/10 5/10 44%
100 SPZ/IV 7/10 0/10 100%
5000 SPZ/SQ 9/10 0/10 100%
a) Three DNA immunizations of BALB/c mice delivered by gene gun (3 shots/immunization, 1 μg plasmid/shot), empty control plasmid 
(pcDNA) or CSP-encoding plasmid (plasmid and immunization described previously [30,34]. All animals were challenged with sporozoites 
from the same batch of infected mosquitoes. Results were confirmed in independent repeat experimentsLeitner et al. Malaria Journal 2010, 9:145
http://www.malariajournal.com/content/9/1/145
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relatively small mosquito-delivered inocula, such
responses can be expected to be amplified when a rela-
t i v e l y  l a r g e  a m o u n t  o f  p a r a s i t e - d e r i v e d  a n d  m o s q u i t o -
derived debris are delivered together. Not surprisingly,
such variability can also be attributed to seasonal factors
that are generally not considered such as changing micro-
bial flora delivered with the isolated sporozoites. Malaria
parasites have repeatedly been found to be surprisingly
susceptible to inflammation, either caused by another
infection or by inflammatory mediators. The sensitivity
of sporozoites to innate immune responses was shown by
Nussler and colleagues 1993 who observed that irradiated
P. yoelii sporozoites could produce a spontaneous intra-
hepatic inhibition of infection for P. berghei sporozoites
that lasted up to three weeks after delivery of the last dose
of irradiated P. yoelii and that this inhibition disappeared
completely after one month [8]. Similarly, activators of
innate immune responses such as CpG oligonucleotides,
ligands for toll-like receptors and acute phase proteins
have been shown to have a significant effect on host sus-
ceptibility and resistance against sporozoite infections
[40-42].
When establishing the IV challenge model, it became
evident that substantially higher numbers of sporozoites
were required for complete infectivity in the three mouse
s t r a i n s  t h a t  w e r e  t e s t e d  t h a n  w e r e  o b s e r v e d  b y  o t h e r
investigators (Table 7). The need for fewer sporozoites to
establish infection in the majority of naïve mice may be
due to several modifications of previously published pro-
tocols. These differences to the procedures described by
others include: (a) the use of mouse serum as the diluent;
(b) keeping sporozoites on ice in cold M199 media con-
taining 5% normal mouse serum (NMS) from the time of
gland dissection until tail vein injection; and (c) the use of
30 gauge needles instead of 27 gauge needles for tail vein
injection of sporozoite suspensions. Furthermore, sporo-
zoites used for the studies presented here were not gradi-
ent-purified, which had been shown to produce more
consistent inocula, but required significantly larger num-
bers of sporozoites likely due to the reduced viability of
the purified sporozoites [6]. After thirty-seven indepen-
dent experiments, the most reproducible challenge
results were performed with sporozoites that were sus-
pended and diluted with 5% NMS in M199 medium.
Sporozoites were held in glass containers on ice until the
time of injection. Under these conditions, a mean ID50 of
50 was reproducibly obtained.
The single infectious bite challenge model was devel-
o p e d  a s  a n  a l t e r n a t i v e  t o  t h e  r e l a t i v e l y  u n r e l i a b l e  a n d
unpredictable IV challenge method. This method does
not require the inclusion of a large number of challenge
control animals in each challenge experiment that need
to be injected with various numbers of SPZ to be able to
reliably determine the success and virulence of the chal-
lenge. This model proved to be significantly more reli-
able, requiring only a single P. berghei ANKA-infected
mosquito to infect most or all challenge controls regard-
less of their genetic background. In contrast, another
study reports the need for at least five mosquitoes to reli-
ably infect 100% of CD-1 mice [16]. Although the reason
for the discrepancy is unknown, the authors of this study
nevertheless conclude that the mosquito bite challenge
should be used rather than IV injection of parasites to
avoid artifacts. For the P. yoelii model of malaria, a recent
report suggests that the IV challenge is more reliable than
the infection of BALB/c mice through mosquito bite,
which in the hands of these investigators required multi-
ple infected mosquitoes [17]. Based on theses unexpected
results, the authors recommend the IV injection of sporo-
zoites as the preferred infection method, however, ignor-
ing the impact on perceived vaccine efficacies.
The method is, however, more labour intensive and this
underscored the need for a reliable, but more efficient
challenge procedure. The use of mixed-sex mosquito-
feeding populations represented a significant improve-
ment since it decreased the time required for an infected
Table 6: Effect of challenge route on perceived vaccine efficacy
Infected/total mice
Groups pCSP(-A)a) pcDNA a)
gene gun vaccination, SQ challenge 0/10 9/10
gene gun vaccination, IV challenge 15/15 12/12
IM vaccination, SQ challenge 5/10 ND
IM vaccination, IV challenge 15/15 13/13
a) BALB/c mice were immunized by gene gun or intramuscular injection with plasmid encoding CSP or empty vector. 10-15 mice/group were 
challenged through the subcutaneous (with 5,000 SPZ) or intravenous (with 300 SPZ) route using the same batch of isolated P. berghei SPZ. 
Shown are the numbers of infected/total number of mice per group. The experiment was independently repeated using different, but 
overlapping challenge doses.Leitner et al. Malaria Journal 2010, 9:145
http://www.malariajournal.com/content/9/1/145
Page 10 of 12
female mosquito to take a blood meal. Specifically, the
addition of two male mosquitoes enhanced the feeding
behaviour of the P. berghei infected female mosquito.
This simple modification decreased the time required for
a normal sixty- to seventy-mouse experiment to four to
six hours for challenge. The observations are consistent
with previous reports that male and female mosquito
interactions can dramatically alter feeding behaviour
[43,44]. Therefore, a sex-linked feeding motivator (e.g.
pheromone, wing beat frequency, etc) that allows infected
female mosquitoes to complete their blood meal more
rapidly must be present when males and females are
together, likely because feeding behaviour among female
mosquitoes is directly linked to egg laying [45].
The present study sought to determine whether a mod-
ified mosquito-bite challenge approach in which mice are
exposed to a single infected mosquito could be developed
as a more reliable, reproducible and more biologically rel-
evant alternative to the routinely used IV challenge
model. After establishing standard parameters required
for making this model highly reliable, it became evident
that despite its effectiveness the logistical hurdles
involved reduce its usefulness. It is significantly more
time and labour consuming than an injection-based chal-
lenge, which limits the size of challenge experiments to
around one hundred mice per experiment. Therefore, a
method was explored that combines the advantages of
the IV and mosquito bite models, the subcutaneous injec-
tion of sporozoites, which generates highly reliable chal-
lenge results. This route, though physiologically much
more relevant than the IV route, surprisingly required
larger numbers of sporozoites than did the IV route, and
the size of the inoculum that is required to produce one
hundred percent infectivity is within a relatively narrow
range. Delivering an increasing inoculum through the
subcutaneous route resulted in a bell-shaped challenge
curve and the drop in challenge efficacy at doses higher
than 4,000-5,000 sporozoites/mouse and is likely caused
by the same factors responsible for the Type 2 failure of
IV challenges, namely inflammatory responses triggered
by excessive amounts of stimulators of innate immune
responses within the inoculum.
Conclusion
The intravenous injection of sporozoites generates highly
variable and poorly reproducible challenge results. Con-
firming the concerns of others [15] this study also reveals
that it drastically affects the perceived efficacy of a pre-
erythrocytic vaccine. The single infectious-bite challenge
as described here for P. berghei is the most reliable and
most relevant readout method for testing the efficacy of
malaria vaccines in animal models. Since it is time and
labour intensive, the subcutaneous injection of isolated
sporozoites at the base of the hind leg presents itself as an
acceptable alternative. This method is rapid, produces
highly consistent challenge results and is much more
comparable to the natural route of malaria infection than
the frequently used IV challenge route.
Both injection-based challenge methods require a care-
ful titration of the inoculum in naive control mice. Such a
titration is required for each IV challenge experiment to
be able to judge the virulence of the inoculum and to
avoid the misinterpretation of vaccination studies. How-
ever, the subcutaneous challenge route appears signifi-
cantly less sensitive to the day-to-day variations in the
inoculum thus allowing the use of an initially established
"standard" dose.
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